These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17062713)

  • 1. Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling.
    Pearse RN
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6274s-6278s. PubMed ID: 17062713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis.
    Daoussis D; Andonopoulos AP; Liossis SN
    Semin Arthritis Rheum; 2010 Apr; 39(5):369-83. PubMed ID: 19095294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of RANKL in bone diseases.
    Anandarajah AP
    Trends Endocrinol Metab; 2009 Mar; 20(2):88-94. PubMed ID: 19185505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.
    Seriwatanachai D; Thongchote K; Charoenphandhu N; Pandaranandaka J; Tudpor K; Teerapornpuntakit J; Suthiphongchai T; Krishnamra N
    Bone; 2008 Mar; 42(3):535-46. PubMed ID: 18166509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bone disease in multiple myeloma and its mechanism].
    Abe M
    Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
    Roodman GD; Dougall WC
    Cancer Treat Rev; 2008 Feb; 34(1):92-101. PubMed ID: 17964729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology of multiple myeloma bone disease.
    Lentzsch S; Ehrlich LA; Roodman GD
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dickkopf-1: a suitable target for the management of myeloma bone disease.
    Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
    Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Osteoporosis and aterosclerosis--is there any pathogenetic association?].
    Zofková I
    Cas Lek Cesk; 2007; 146(3):246-50. PubMed ID: 17419308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Key roles of the OPG-RANK-RANKL system in bone oncology.
    Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biology of RANK, RANKL, and osteoprotegerin.
    Boyce BF; Xing L
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANKL signaling in bone physiology and cancer.
    Dougall WC
    Curr Opin Support Palliat Care; 2007 Dec; 1(4):317-22. PubMed ID: 18685382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
    Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O
    Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone destruction in multiple myeloma.
    Matsumoto T; Abe M
    Ann N Y Acad Sci; 2006 Apr; 1068():319-26. PubMed ID: 16831932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New potential targets for treating myeloma bone disease.
    Roodman GD
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils.
    Poubelle PE; Chakravarti A; Fernandes MJ; Doiron K; Marceau AA
    Arthritis Res Ther; 2007; 9(2):R25. PubMed ID: 17341304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of Wnt proteins in arthritis.
    Schett G; Zwerina J; David JP
    Nat Clin Pract Rheumatol; 2008 Sep; 4(9):473-80. PubMed ID: 18756273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
    Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.